RxDoctor Payments Data

Anant Agarwalla, MD

Gastroenterology · Wallingford, CTNPI 1326458589

Payments from drug & device makers

$6,859in general payments, 2019–2025

Across 305 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$757
  • Takeda Pharmaceuticals U.S.A., Inc.$735
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$709
  • Gilead$516
  • Sanofi$344
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$6,61896%
  • Education$2414%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,859 in reported general payments places this provider in the 65th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$119,009
Medicare patients
254
Services billed
2,824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$357,039
Humira(Cf) PenAdalimumab17$143,109
OcalivaObeticholic Acid12$115,309
ZenpepLipase/Protease/Amylase20$50,589
LinzessLinaclotide41$30,788
Mesalamine36$13,391
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates157$9,535
Pantoprazole Sodium290$6,033
Dexlansoprazole DrDexlansoprazole16$6,004
Omeprazole353$5,074
Lubiprostone12$3,792
Sucralfate66$3,125
Ursodiol21$2,282
Famotidine120$1,336
Lansoprazole19$1,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$757$357,03913 claims
Intercept Pharmaceuticals, Inc.Ocaliva$160$115,30912 claims
Aimmune Therapeutics, Inc.Zenpep$48$50,58920 claims
AbbVieLinzess$1,327$30,78841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Wallingford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →